Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTERACT-PLUS neoadjuvant intraperitoneal irinotecan plus mFOLFOX4-bevacizumab before CRS-HIPEC
NL-OMON58745Phase 2Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Oct 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan, bevacizumab, fluorouracil, folinic acid and oxaliplatin in colorectal cancer (CRC), sponsored by Erasmus MC. Primary endpoint: Feasibility of completing protocol treatment. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
irinotecanbevacizumabfluorouracilfolinic acidoxaliplatin
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON58745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58745.